Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00109707
Status:
COMPLETED
Last Update Posted:
2021-06-29
First Post:
2005-05-02
Brief Title:
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia CML or Other Hematologic Malignancies
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Systemic Mastocytosis |
| Chronic Myelogenous Leukemia |
| Acute Lymphoblastic Leukemia Philadelphia Chromosome Positive |
| Hypereosinophilic Syndrome |
Keywords:
| Name | View |
|---|---|
| CML in blast crisis | View |
| CML in chronic phase | View |
| CML in accelerated phase | View |
| Gleevec resistance | View |
| Gleevec intolerant | View |
| Gleevec and CML | View |
| imatinib resistance | View |
| imatinib intolerant | View |
| Hypereosinophilic Syndrome | View |
| Systemic Mastocytosis | View |
| Chronic eosinophilic syndrome | View |
| Philadelphia chromosome positive acute lymphoblastic leukemia | View |
| HES | View |
| CEL | View |
| CML | View |
| SM | View |
| Ph ALL refractory to standard therapy | View |
| PhALL relapsed | View |
| AMN107A | View |